Core Viewpoint - The company, Huajian Medical (1931.HK), has proposed to seek shareholder approval for a purchase authorization to invest in cryptocurrencies, particularly Ethereum (ETH), as part of its asset allocation strategy and business development plans [1] Group 1: Company Actions - The company's board believes that purchasing and holding cryptocurrencies is a crucial step in solidifying its Ethereum reserves and accelerating the development of the ivd.xyz exchange ecosystem [1] - The board has recommended that shareholders approve a resolution allowing the company to potentially purchase cryptocurrencies over a period of 36 months, with a total purchase limit not exceeding 3 billion HKD [1] Group 2: Strategic Alignment - The potential cryptocurrency purchases and the authorization for such purchases are considered to align with the company's long-term development strategy and the overall interests of its shareholders [1]

Core Viewpoint - The company, Huajian Medical (01931), is seeking shareholder approval to authorize the board to purchase cryptocurrencies as part of its asset allocation strategy, particularly to strengthen its Ethereum (ETH) reserves and accelerate the development of the ivd.xyz exchange ecosystem [1] Group 1 - The board believes that purchasing and holding cryptocurrencies is a crucial step for the company's business layout and development [1] - The proposed authorization for cryptocurrency purchases will be valid for a period of 36 months from the date of the special resolution passed by shareholders [1] - The total amount allocated for cryptocurrency purchases will not exceed HKD 3 billion [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責 任。 一、 戰略升維之背景及商業邏輯 戰略回顧 茲提述本公司於二零二五年七月十七日發佈之自願性公告及二零二五年 七月二十日發佈之戰略進展相關自願性公告，內容有關本集團啟動「IVDNewCo Exchange」－全 球 首 個 聚 焦 醫 療 創 新 藥NewCo高科技資產的RWA交易所生態 及「IVDD」穩 定 幣 計 劃，致 力 於 以「NewCo +RWA」Web3交易所生態運作模式 徹 底 改 寫 醫 療 創 新 藥 行 業 的 資 本 效 率 與 全 球 化 進 程，解 決 醫 療 創 新 藥 行 業 長 期 面 臨 的 融 資 效 率 低、資 產 流 動 性 差 及 全 球 化 門 檻 高 等 痛 點。 – 1 – 董事會謹此宣佈，已正式將此「NewCo +RWA」Web3交易所命名為「ivd.xyz」（ivd. xyz交易所），本公司矢志構建 ...

Group 1 - The core strategy of the company is to launch a "Global Enhanced Ethereum Vault" with a downward protection mechanism, positioning Ethereum (ETH) as a strategic reserve asset [2][5] - The company has entered into a strategic partnership with HashKey Group, which will provide support for large-scale ETH transactions and explore the integration of crypto assets with real-world assets (RWA) [5][10] - The company has invested 149 million HKD to purchase 5,190 ETH and plans to continue increasing its holdings through a dollar-cost averaging strategy, with an approved budget of 880 million HKD [5][10] Group 2 - The "Active Coin Generation" feature is a key highlight of the company's Ethereum Vault strategy, allowing for the tokenization of innovative drug intellectual property (RWA) and trading on the ivd.xyz exchange [8][9] - The ivd.xyz exchange is the first Web3 exchange focused on medical innovation drug RWA, combining centralized and decentralized exchange features to support cross-chain trading [8][9] - The company's downward protection mechanisms include an ATM mechanism, a priority structure, RWA price buyback commitments, and a clinical VC safety net, providing comprehensive protection for investors [9] Group 3 - The Ethereum Vault strategy opens up a potential market capitalization growth space of over 100 billion HKD, drawing parallels with MicroStrategy's Bitcoin strategy, which saw an 80-fold increase in market value [10] - The company’s current market capitalization exceeds 13 billion HKD, indicating significant growth potential compared to MicroStrategy and Metaplanet [10] - The strategy aligns with the Hong Kong Monetary Authority's Ensemble project and China's innovation drug export strategy, aiming to lower financing costs and accelerate technology transfer [11]

Core Viewpoint - The company has officially launched a strategic upgrade to create a "Global Enhanced Ethereum (ETH) Treasury" with a focus on medical innovation and asset tokenization [1][2]. Group 1: Strategic Overview - The company aims to integrate Ethereum (ETH) as a core reserve asset to enhance the efficiency of medical innovation drug development and asset allocation [3][7]. - The new "ivd.xyz" exchange will focus on high-tech assets in global medical innovation, facilitating the tokenization of real-world assets (RWA) [1][2]. Group 2: Mechanisms and Protection Strategies - The board has authorized the management to establish a "verifiable, executable, and quantifiable" seven-layer protection mechanism to safeguard shareholders and RWA holders [5]. - Additional strategies include a "three-layer enhancement engine" to transform ETH assets from passive holding to active income generation and reinvestment [5][6]. Group 3: Market Context and Trends - The strategic move aligns with global trends in cryptocurrency asset allocation, particularly among institutional investors, and responds to regulatory frameworks in regions like Hong Kong and the U.S. [4][6]. - The company has drawn insights from leading practices in the cryptocurrency asset reserve field, referencing successful models from various global firms [6][7].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責 任。 IVD Medical Holding Limited 華檢醫療控股有限公司 （於開曼群島註冊成立之有限公司） （股份代號：1931） 自願性公告 打 造「全 球 增 強 版 以 太 坊（ETH）金 庫」、升 維 公 司 全 球 戰 略、為 生 態 參 與 者創造價值 本 公 告 由 華 檢 醫 療 控 股 有 限 公 司（「本公司」或「華檢醫療」，連 同 其 附 屬 公 司 統 稱「本集團」）董 事 會（「董事會」）自 願 作 出，旨 在 向 股 東、潛 在 投 資 者 及 市 場 各 方 全 面 闡 述 本 集 團 最 新 戰 略 升 級 暨 升 維 舉 措－經 董 事 會 決 議 通 過，本 集 團 正 式 啟 動「具 備 下 行 保 護 機 制 的 全 球 增 強 版 以 太 坊（ETH）金 庫」戰 略（「以 太 坊（ETH） 金庫戰略」） ...